Share on

APAC Chlamydia Infection Diagnostics and Therapeutics Market Research Report – Segmented By Product Type, End User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends and Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 4962
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the Asia Pacific Chlamydia Infection Diagnostics and Therapeutics market was around USD 0.48 billion in 2023. It is expected to grow at a CAGR of 6.7% to reach USD 0.66 billion by 2028. It captures 20% of the global market. 

The prevalence of chlamydia infection, sexually transmitted diseases (STDs), and a variety of other infections are rising, driving growth for novel diagnostics and therapeutics, particularly in APAC, increase in research and development activities, increased health awareness, combined with rising healthcare spending, primarily for academic research are majorly propelling the growth of the chlamydia infection diagnosis and therapeutics market in APAC. The risk of infection among the young generation fuels the demand for infection diagnostics, which is expected to propel the Asia Pacific chlamydia infection diagnostics and therapies market forward. An increase in government-sponsored initiatives for spreading awareness and measures such as free diagnostic camps are fueling the growth of the chlamydia infection treatment market. The demand for frequent health check-ups has increased, as has public awareness of the importance of disease screening, expanding the number of diagnostic facilities, and the availability of Direct-to-Consumer (DTC) testing kits. As a result of the increased use of disease screening, the market for chlamydia infection treatment is predicted to grow. The growing desire for rapid and effective diagnostic tests and treatments to treat this rapidly growing patient pool drives the APAC market for chlamydia infection diagnostics and therapeutics.

Despite the significance of regular STD testing, people often avoid it due to social stigma; this can result in lower screening, prevention, and care, restricting the chlamydia infection treatment market growth in this region. In addition, patients commonly suppress details about their sexual lives from doctors, further limiting the market for chlamydia infection treatment.

This research report on the APAC Chlamydia Infection Diagnostics and Therapeutics market has been segmented & sub-segmented into the following categories:

By Product: 

  • Diagnostics
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
    • PCR
  • Therapeutics
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

By End User: 

  • Diagnostics
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Therapeutics
    • Hospital Pharmacies
    • Drugstores
    • Retail Pharmacies
    • Online Pharmacies

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

APAC was the third-largest market for Chlamydia Infection Diagnostics and Therapeutics across the globe in 2020 and is predicted to grow with the highest CAGR in the forecast period. The availability of cheaper products compared to western developed countries, new and improved government initiatives for better healthcare, an increasing number of patients, and others. are the reasons attributable to the observable trend mentioned above. 

The market in the Asia Pacific is expected to be favored by factors such as a massive pool of potential patients, the implementation of government initiatives aimed at improving health care access, the rising incidence of chlamydia infection, improved infrastructure, and rising health care expenditure. The growing infrastructure and the incidence of chlamydia sexually transmitted diseases are credited with driving market expansion in the Asia Pacific. According to the World Health Organization's "Global incidence and prevalence of selected curable sexually transmitted infections - 2008," 8 million adults were infected with Chlamydia in the South East Asia region in 2008. The Asia-Pacific chlamydia infection treatment market is expected to develop rapidly due to rapidly rising and improved healthcare infrastructure, increased need for medical screening, and higher awareness of STDs. Furthermore, the market's expansion is aided by the rising biopharmaceutical market, more excellent government backing, large expenditures by key market participants, and developing R&D infrastructure. Products that have been approved by influential government agencies benefit market leaders. Expanding operations into high-growth prospective regional markets, product launches, collaborative partnerships, and acquisitions are just a few of the primary growth methods firms use to strengthen and secure their market position.

KEY MARKET PLAYERS:

Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company are some of the noteworthy companies operating in the APAC Chlamydia Infection Diagnostics and Therapeutics market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample